Latest News

Tilray's transformation is still ongoing, but it just reached a critical milestone.

Musk just provided a mind-boggling 2027 revenue forecast for Space Exploration Technologies.

Netflix wants to claw back market share from YouTube, which has made considerable gains.

The earnings report and call were short on razzmatazz but long on substance, strengthening the investment case for the stock.

Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

Deep Fission (NASDAQ:FISN) outlined its development, regulatory and financing plans for underground nuclear power projects during its October 2026 business update, targeting initial commercial power from a pilot project in Parsons, Kansas, by December 2027 and broader deployments beginning in 2028.

The company's third quarter was marked by double-digit growth.

Forecasts point to a high likelihood of continued gains, but possible headwinds could interrupt growth.

If things seem too perfect on Wall Street, they probably are.

For its stock to take off, Samsara must transform customer value into profitable growth.

The conglomerate bought back its shares in June for around $488 each. Are they still a buy at a record?

You might be able to turn that $10,000 into $115,347 -- or more. (Or less.)

The power of dollars compounding over 20 years can turn a small dividend income into a huge one.

Investing in just this one exchange-traded fund (ETF) for the past 25 years could have set you up for serious financial security.

The stock has been on a great run this year.

Adagene (NASDAQ:ADAG) is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant investigator-sponsored trial in Singapore, Chief Strategy Officer Mickael Chane-Du said during a Chardan conferen

Bloom Energy has benefited from tailwinds from data centers for power solutions. Here's what the company must do to continue delivering for investors.

Exceeding expectations on the bottom line can't compensate for this shortcoming -- at least in some investors' eyes.

Many AI stocks beat the Nasdaq Composite this year, and these three picks look like they can repeat the feat in 2027.

Earnings jumped 22% last fiscal year. Why would I still want the stock around 12% cheaper?

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Annaly and AGNC are getting hit by rising rates; is that an opportunity for investors or a valid recognition of risk?

Just because you can multiply daily moves, doesn't mean you should.

The shocking part is that the gift is only a drop in the bucket compared to the founder's total wealth.

You don't have to wait until December to find out how much your Social Security check will grow.